Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

Phase I Clinical Trial

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer
Trial Number: 04485013
Trial Status: Call Proj Mgr

Learn more about this clinical trial.

Participating Locations